

Index

A

a priori hypothesis, defined 71
 absolute risk reduction (ARR) 123
 abstract data 72
 academic-initiated trial 196
 accounting 226
 accuracy, vs. precision 127
 adjudication
 and bias 237, 240
 central 238
 defined 220
 examples 239
 Internet 241
 in manual of operations 263
 quality assurance in 240–241
 requests 183–184
 resources 239
 time required 240
 adjudication committee 265
 administration of trials/studies 265
 costs 186–191
 administrative assistant 217, 218
 adverse drug reaction 207
 adverse events 149, 199, 207
 in manual of operations 263
 and recall bias 53
 reporting 104
 serious 199
 adverse events form 254
 agreement
 chance-independent 95
 between groups 96
 interobserver 94
 magnitude 98
 proportion 93–94, 95
 between reviewers 72, 94
 see also reliability
 alpha, Cronbach's 94, 95
 alpha error 15, 132, 136, 149, 276, 280–281
 alternative hypothesis 275, 276
 analysis of variance (ANOVA)
 multiple comparison procedures 296–297
 one-way 294–298
 two-way 298–300
 analytic studies 170
 appraisal
 criteria, for RCTs 66
 of economic analyses 83
 approval, drugs and devices 207
 association funding 211
 attitude, in research 153
 attrition bias 57
 audits, clinical trials 197, 206–207
 authorization code 262

B

background questions 68, 158
 bar graphs 271
 baseline characteristics form 251
 Belmont Report 5
 best evidence
 resources for finding 16
 use of 42
 beta error 15, 136, 149, 276, 280–281
 bias 32
 and adjudication 240
 defined 37, 220, 237
 types, in primary studies 71
 see also attrition bias; expertise bias; recall bias; selection bias
 binomial distribution 273
 biostatistician 216, 233
 and sample size calculation 149
 biostatistics 269
 blind studies
 diagnostic 87
 history 4
 blinding 61, 165–166
 appraisal criteria 66
 defined 216, 237
 block randomization 168
 Bonferroni correction 178
 box-and-whisker plots 271
 budgeting 198, 226
 adjudication costs 240
 for research studies 181–195
 see also costs

C

calculations, statistical 305–308
 Canadian Institutes of Health Research (CIHR)
 and DMC 230
 and funding 210
 Canadian Occupational Performance Measure (COPM) 118
 case report forms (CRFs) 82, 248–257
 administration 265
 content 249
 development stages 248
 instructions for completing 256
 review 256
 style and layout 255–256
 case reports 35
 case series 35
 clinical 47–48
 defined 204
 features of good design 47
 case-control study 34–35, 49–54, 171, 173–175
 analysis 51–52

 data elements required 54
 defined 39, 49
 design 173
 example 53, 174
 limitations 52–53
 when to use 52
 cases
 incident, defined 50
 prevalent, defined 50
 selection 50
 standard 249
 categorical data 270, 282
 categorical outcome 178
 categorical variables, vs. continuous 301
 centile 271
 central methods center
 costs 181, 184–193, 192
 data filing 183–184
 defined 222, 259
 functions 223–228
 Internet communications 227, 228
 necessity 222–223
 personnel 215–217
 role 222–229
 staff 223
 staffing costs 186
 central outcomes adjudication committee 220–221
 costs 192
 centralized randomization 168
 chi-square analysis/test 276, 283
 with Excel 285–286
 classes of data 270
 classifications, research design 31–36
 clinical case series 47–48
 clinical centers/sites
 communication with 226–228
 contracts with 226
 cost breakdown 184
 costs 181
 payments to 182–184
 personnel 217–218
 preparation 182
 reimbursement 266
 clinical database system, costs 187
 clinical effectiveness 82
 clinical practice
 guidelines 197, 205
 and research questions 153–154
 clinical proficiency, and EBM 14–15
 clinical research
 coordinator 218
 history 3–4
 need for 1–27
 planning 143–214
 principles 29–142
 proposal requirements 145–152

- see also* studies; study design
 clinical scenario 86–90
 clinical sites *see* clinical centers/sites
 clinical trials
 audits 197
 monitoring 206–207
 objectives 259
 participation agreement 212
 participation offer review 194–195
 phases 196, 203–204
 see also clinical research; studies
 clinicians
 blinding 165
 skills needed in EBM 10
 cluster randomization, defined 62–63
 Cochrane database 11, 16
 coefficient of determination (r^2)
 291–292, 304
 see also correlation coefficient
 cohort, defined 55
 cohort study 34, 171–173
 critical appraisal 173
 defined 39
 design 172
 example 14, 173
 prospective 55–58
 retrospective, example 56
 co-investigator 185, 216
 collaborators 216
 collection of costs, in economic analysis 82
 communication
 around the clock 227
 with clinical centers 226–228
 costs 188–189
 defined 227
 with review board 199
 community of science (COS) web site 211
 computer hardware, costs 186–187
 concealed treatment 223
 concealment, defined 60
 conditional probability 121–122
 conduct analysis 72
 confidence intervals (CI) 72, 275
 advantages 128–130
 calculating 306
 and clinical significance 141–142
 of correlation coefficient 304–305
 defined 15, 127–131, 304
 for different parameters 128
 example use 129–130
 and statistical significance 129
 width 128
 confidentiality, for study participants 201–202
 conflicts of interest checklist 233–234
 confounding variables 53, 57, 172, 180
 consent *see* informed consent
 consistency, instruments 93
 construct validity 108–109
 content validity 108
 contingency tables 286
 continuous outcome 178, 179
 continuous variables/data 270, 282
 vs. categorical 301
 control event rate (CER) 122, 123
 Controlled Clinical Trial Database (Cochrane) 11
 controlled experiments, history 3–4
 convergent validity 109
 "cookbook" medicine 14
 coordinator 185, 216
 coordinator, costs 185
 co-principal investigator 185, 215–216
 correction
 Bonferroni 178
 and r^2 304
 correlation 301–308
 defined 301
 directions 302
 correlation coefficient (r) 291–292, 302–305
 assumptions 304
 calculating 305–306
 defined 302
 hypothesis test for 305
 interpreting 303
 intraclass 95
 P value from 306–308
 properties 303
 see also coefficient of determination
 cost collection, in economic analysis 82
 cost discounting 83
 cost reduction, and EBM 17
 cost-benefit analysis 46, 81
 cost-effectiveness analysis (CEA) 78–80
 see also incremental cost-effectiveness ratio
 cost-minimization analysis 77–78
 costs
 adjudication 240
 central methods center 184–193
 clinical trial participation 194
 ethics committee approval 198
 see also budgeting
 cost-utility analysis (CUA) 80–81
 see also incremental cost-utility ratio
 criterion validity 109
 Cronbach's alpha 94, 95
 crossover trials 33
 design 63–64
 crossovers, reducing 167
 cross-sectional studies 35, 171, 175–176
 cultural barriers, HRQL 110
- D**
- data
 analysis, in reliability study 98
 collection 183, 248
 continuous vs. discrete 270
 filing, central methods center 183–184
 management *see* data management
 monitoring, interim 230
 pooling, defined 69
 preparation 234
 presentation 121–123, 234
 types 270, 282
 data analyst 216–217
 data management 243–247
 centralized 224–226
 costs 188
 by fax 244–246
 by Internet 243–244
 by mail 246–247
 data manager, costs 185–186
 data monitoring committee (DMC) 207, 230–236, 265
 costs 192
 defined 230
 functions 231
 history 230
 independence 232
 meetings 234–235
 membership 232–234
 need for 231–232
 recommendations 235–236
 data safety and monitoring board 219–220
 database manager 217
 database system, costs 187
 DataFax Management System 224, 244–246
 decision algorithm, Jadad 74, 75
 decision analyses 41
 decision models, levels of evidence 39
 degrees of freedom 296
 Department of Health and Human Sciences (DHHS) guidelines 5, 6
 dependent variables 277, 288
 vs. independent 301
 descriptive statistics 270
 descriptive studies 170
 design of research *see* study design
 determination coefficient *see* coefficient of determination
 deviation from protocol 199
 device evaluation 203–209
 approval 207
 example study 208–209
 review process 205–206, 208
 devices, federal regulation 205
 diagnostic studies 85–90
 hierarchies of study design 41
 levels of evidence 38
 and patient care 89
 diagnostic tests
 critical appraisal 86
 reproducibility 89
 uncertainty 86–87
 dichotomous outcome 178, 179
 dictation script 260
 differences, in outcome values 281–282
 direct costs 195
 discounting of costs, in economic analysis 83
 discrete data 270
 disease-specific measures
 HRQL 118
 orthopaedic trauma 116–117
 outcome 103
 distribution *see* normal distribution

- documents, for case reports 248
- double-blind studies, history 4
- dropouts, accounting for 179
- drug evaluation 203–209
 approval 207
 example study 208–209
 review process 205–206, 208
- drugs, federal regulation 205
- E**
- early withdrawal form 255
- EBM *see* evidence-based medicine
- economic analyses 77–84
 appraisal 83
 conducting 81–83
 hierarchies of study design 41
 levels of evidence 39
 perspectives in 82
 types 77
- economist 216
- education courses, EBM 25
- effect size 139
 defined 15
 and *P* value 129
- effectiveness 82, 204
- efficacy, defined 204
- EMBASE 162
- EQ-5D 114
- error
 in measurement 92
 random 220
 statistical, defined 135
 types 135–136
see also standard error of the mean
- estimation 275
- ethics
 approval 198, 204–205
 principles 5
 review 155
- ethics committee
 defined 204
 responsibilities 201
 role 198–199
- EuroQol-5D 114
- event, defined 128
see also adverse events; single-event probability
- event rates 122
- evidence
 hierarchy 10, 13, 31, 37–49
 implementation in practice 20–26
 reappraised 159
 sources 159
- evidence-based medicine (EBM) 8
 challenges to 8, 10
 and clinical proficiency 14–15
 and cost reduction 17
 courses in 25
 criticism of 9, 10, 17
 five As of 9
 guidelines 21
 and individual patients 16
 key concepts 9
 myths and misconceptions 12–18
 need for 9
 practice 31
 and RCTs 13–14
 resources 11, 22–25
 and statistical expertise 15
 surgery 8–11
 vs. traditional approaches 8–9
 usefulness for individual patients 16
- Excel program
 and chi-square test 285–286
 and *t* test 283–285
- Excerpta Medica database (EMBASE) 162
- exclusion criteria 72, 146–147, 260
- expenses
 clinical sites 184
 for research studies 193
- experimental event rate (EER) 122, 123
- experimental studies 32–34, 45
 vs. observational 44–45
- experiments, controlled, history 3–4
- expertise bias 47
- expertise-based design 62, 166
- explanatory trials 60
- F**
- F test 292
- face validity 108
- factorial design trials 33, 64–65
- Fagan's nomogram 89
- faxes
 costs 187–188
 and data management 224, 244–246
- financial manager 217
- follow-up
 costs 183
 final visit 265
 loss to 166, 264–265
 patients 263–265
 report 253
- Food and Drug Administration (FDA)
 drug and device approval 205
 guidelines 5, 6
- foreground questions 69, 158
- forest plots 72–74
- forms, for case reports 248–257
- foundation funding 211
- freedom, degrees of 296
- frequencies, natural 123
- frequency distribution 271, 296, 305
- funding, strategies for obtaining 210–214
- G**
- Garden index 94, 95
- GCP *see* good clinical practice
- generalizability, defined 69
- generic measures
 defined 112
 outcome 102–103, 112–115
- good clinical practice (GCP) 197, 205
- Google Scholar 160
- government funding 210–211
- grades of recommendation 42
- grant applications, tips 212–213
- graphs, statistical, interpretation 289–290
- gray literature 71
- guidelines
 clinical research 5–6
 evidence-based 21
 good clinical practice 197
 and question formulation 159
 for research protocol 145
- H**
- Health Canada 205
- Health Utilities Index (HUI) 114–115
- health-related quality of life (HRQL) 80
 administering questionnaires 264
 cultural and language barriers 110
 disease-specific outcomes 116–120
 generic measures 112–114
 interviews 183
 joint-specific measures 118
 in manual of operations 263
 measures, responsiveness to change 109–110
 modes of administration 103–105, 148
 as outcome measure 102, 107–111, 148
 patient-specific measures 118–119
 regional measures 117–118
 selection of measures 147
 studies, reviewing and reporting 110
 utility measurement 112, 114–115
- Helsinki Declaration 5, 197
- heterogeneity
 defined 69, 71
 statistical test for 74
- hierarchy of evidence 10, 13, 31, 37–49
- hierarchy of research/study designs 21, 37–43
 Guyatt and Rennie 39
 Schunemann and Bone 39
 for treatment studies 39–40
- histograms 271
- history
 clinical research 3–4
 data monitoring committee 230
- human welfare, ethical principle 5
- hypothesis
 alternative 275, 276
 a priori 71
 defined 280
 formulating 145
 test for *r* 305
 testing 132, 133, 135–138, 275–277
see also null hypothesis
- I**
- ideas, for research 153–154
- implementation of research evidence 20
- imprecision, in statistical estimates 127, 128
- incidence study 34
- incident cases 50
- inclusion criteria 72, 146–147, 260

- incremental cost-effectiveness ratio (ICER) 78
- incremental cost-utility ratio (ICUR) 80–81
- independent variables 277, 288
vs. dependent 301
- indirect costs 195
- industry funding 211–212
- industry-initiated/sponsored trials 196, 212
- inference, statistical 276
- informed consent 5, 15, 183, 200–201, 205
form 183, 199–200
obtaining 200–201
proxy 262
see also withdrawal from study
- inspection, defined 207
- institutional review board 6
- instruments
internal consistency 93
and reliability 92
- intention-to-treat principle 166–167
- interim data 230, 234
- internal consistency 107, 108
- International Clinical Trials Registry 6
- International Conference on Harmonization (ICH) 197
- Internet
for adjudication 241
for communication with clinical sites 227, 228
for data management 243–244
randomization system 189, 224–225
- interobserver agreement/reliability 93, 94, 238
- interquartile range 271
- intrerrater reliability 107, 108
- interventions, in manual of operations 262–263
- intraclass correlation coefficient (ICC) 95, 97, 107
- intraobserver reliability 93, 238
- investigator-initiated trial 196
- investigators
defined 205
meeting of 229
principal 185, 215, 217–218
role 197
- J**
- Jadad decision algorithm 74, 75
- joint-specific measures, HRQL 118
- K**
- kappa coefficient 94–95
- L**
- language barriers, HRQL 110
- learning curve 47
- least-squares regression line 291
- levels of evidence 37–49
- likelihood ratios, diagnostic tests 88
- linear regression analysis 290–291
- literature searching 10, 16, 71–72, 86, 158–163
comprehensive 146
critical appraisal 98–99
field descriptions and tags 162
and research questions 154
- local funding 211
- loss to follow-up 166
- M**
- magnitude of effect *see* effect size
- mail, for data management 246–247
costs 190
- maintenance costs, communication systems 188–189
- management trials 60
- manual of operations 190, 258–267
appendix 266
background information 259
communication 259
defined 258
patient status evaluation 259–260
- manuscript preparation, systematic reviews 74
- mean 272, 273
and proportions 279–287
standard error of 274, 275
statistical 271
- measurement 91
- measurement error 92
- measures *see* outcome measures/parameters
- median 271, 305
- medical literature *see* literature searching
- Medical Subject Headings (MeSH) 162
- medications log 251
- MEDLINE 160–162
- meetings, costs 191–193
- mentoring, for grant applications 212
- meta-analysis 21, 35, 68–76
conducting 70–74
defined 82, 146, 213
hip fractures, interpreting 130–131
- methodology, selecting 146–149
- Microsoft Excel
for chi-square test 285–286
for *t* testing 283–285
- modeling, statistical 277
- monitoring, clinical trials 206–207
- multicenter randomized trials
advantages 223
budget preparation 181–193
committees 219
see also randomized controlled trials
- multivariate regression analysis 52, 180, 277
- N**
- narrative review 68
- National Cancer Institute (NCI), trials programs 6
- National Institutes of Health (NIH) and DMC 230
- and funding 210
- natural frequencies 123
- negative trials/studies 72, 129–130
- newsletter, for clinical centers 227
- n-of-1 trials 9, 34, 65–66
defined 9, 40
example 66
- noise, and statistical significance 292, 295
- nominated principal investigator 185, 215
- nonparametric methods 272–273
- nonrandomized studies
planning 170–176
vs. randomized 44–46
- normal distribution 273, 274
defined 305
- Nottingham Health Profile 114
- null hypothesis 132, 156, 275, 276, 280
defined 305
see also hypothesis
- number needed to treat (NNT) 15, 123
- numerical data 270
- Nuremberg Code 5
- O**
- objectives, of clinical trials 259
- observational studies 34, 170, 171
data elements required 54
disadvantages 45
vs. experimental 44–45
vs. RCTs 13, 45–46
types 34–35
- observations 270
- odds ratio 122–123
2 × 2 table 174
calculation 51, 52
defined 15, 51
and phi 95
- office costs, in research studies 190–191
- one-tailed tests 282
- one-way analysis of variance 294–298
example 297–298
- open trials 32
- orthopaedic medicine, EBM resources 22–25
- orthopaedic surgery, and RCTs 59
- orthopaedic trauma, specific instruments 116–117
- orthopaedic trials, questions in 13
- outcome measures/parameters 147
appropriate 103–104
clinical vs. statistical 140
continuous vs. dichotomous 147
disease-specific 116–120, 147
examples 148–149
for patients 101–106, 111
primary vs. secondary 177–178
for surgeons 111
understanding 101–120
usefulness 107–111
values, determining differences 281–282

- outcomes
 adjudication, separate 237–242
 classification 101–106
 clinical 104
 of disease, levels of evidence 38
 patient follow-up 263
 perspectives 101
 primary 238
 types 178
- outliers, effect of 304
- OID 162
- Oxford Centre for Evidence-Based Medicine 25, 37
 levels of evidence tables 37, 38–39
- Oxman and Guyatt index 74
- P**
- P* value 275, 280
 calculating 306–308
 and confidence interval 127
 defined 15, 132–134, 280, 305
 example use of 133
 limitations 133–134
 and magnitude of agreement 98
 meaning 281
 see also significance
- paired *t* test 282–283
- parallel trials 33, 63
- parametric methods 272
 confidence intervals for 128
- participants in studies
 rights 201
 selection, in reliability study 96
- participation offer, clinical trials 194, 212
- patients
 application of evidence 21
 blinding 165
 confidentiality 201–202
 consent 183
 daily record 183
 discussing results with 125
 evaluating 259–260
 expenses for participation 184
 following in hospital 183
 follow-up 263–265
 individual, and EBM 16
 information needed for consent 200–201
 perspective on outcome 101, 111
 recruitment 183
 reminder form 263, 264
 rights as participants 201
 safety, reporting 207
 screening 183
 selection, in reliability study 96
 shadow chart 202
 status documentation 262
 see also informed consent
- Patient-Specific Index (PASI) 118–119
- patient-specific measures, HRQL 118–119
- payments to clinical sites 184
 see also budgeting; costs
- Pearson correlation (*R*) 94, 95, 302
 example 305
 peer-review system 211
 percentage agreement 93–94
 performance measures 147
 pharmaceutical industry 196
 phases, of clinical trials 196, 231
 defined 203–204
- phi 95
- phone costs 189
- PICO questions 158
- pilot study
 budget 193
 defined 211
- pocket protocol 191
 defined 216
- Poisson distribution 273
- pooling of data
 defined 69
 software for 72
- populations 272–274
 normal distribution 274
 and samples 269
- positive trials/studies 72, 129–130
- posters, for potential study patients 260, 261
- postoperative information form 253
- power of studies/tests 136–137, 149, 276
 defined 15, 68
- pragmatic trials 60
- preappraised evidence 159
- precision, vs. accuracy 127
- predictive value 88–89
- predictor variables 180
- preoperative information form 251–252
- prevalence, defined 175
- prevalence studies 35
- prevalent cases, defined 50
- primary outcome 238
- primary study
 bias types 71
 defined 69, 72
- principal investigator 185, 215
 site 217–218
- printing costs, research studies 190
- probability
 conditional 121–122
 defined 121
 distributions 272–274
 ratios, diagnostic tests 88
 single-event 121
 types 121–122
- prognostic studies 179–180
 hierarchies of study design 41
 levels of evidence 38
- proportion agreement 93–94, 95
- proportions 270
 and means 279–287
- proposal, research
 example format 150
 requirements 145–152
- prospective cohort study 55–58
- prospective study, defined 56
- protocol
 administrative costs 190
 deviations 199, 265
 pocket 191, 216
 for RCT, organizing 150–152
 surgical, standardization 164–165
 violation 199
- protocol deviation form 254
- proxy consent 262
- publication bias 14, 72
 defined 14
- publications, preparation 229
- PubMed searches 16, 160–162
- Q**
- quality assurance, in adjudication 240–241
- quality control reports 224, 226
 with DataFax system 245–246
 responding to 183–184
- quality of life see health-related quality of life
- Quality of Well-Being Scale (QWB) 115
- quality-adjusted life years (QALY), defined 80
- questionnaires
 administering 264
 self-administered vs. interview 113
 see also health-related quality of life
- questions, for research
 answerable 158–159
 characteristics of good 154–156
 clinical 9
 defining 70, 96
 "FINER" characteristics 154–155
 foreground vs. background 68–69, 158
 formulating 145–146
 four elements 154
 generating 156
 guidelines as sources 159
 identifying 153–157
 "PICO" model 154
 refining 156
- QUORUM statement 74
- R**
- r* see correlation coefficient
- R* see Pearson correlation
- r*² see coefficient of determination
- random error, defined 220
- randomization 167–168, 183
 automated 223
 centralized 223–224
 cluster 62
 costs 188–189
 defined 204
 form 250–251
 instructions 262
 Internet system 189, 224–225
 procedure, in manual of operations 260
 stratified 165
 telephone system 189, 224
 unit 62–63, 262

- randomized controlled trials (RCTs) 22, 32–33, 59–67
 appraisal checklist 66
 budgeting for 181–195
 committees 219
 crossover trial 63–64
 defined 13, 39, 60, 70, 82, 237
 designs 63–66
 and EBM 13–14
 factorial design 64–65
 history 4
 multicenter, budget preparation 181–193
 n-of-1 trials 65–66
 vs. nonrandomized 44–46
 vs. observational studies 45–46
 in orthopaedic surgery 59
 parallel trial 63
 planning 164–169
 protocol organization 150–152
 total expenses 193
 types 33–34
- range, statistical 271
- raters, selection, in reliability study 96
- rates, vs. proportions 270
- rating session, in reliability study 97–98
- recall bias 53, 174
- recommendations
 data monitoring committee 235–236
 grades of 42
- recruitment 183
- recruitment package 260
- reference standards, in diagnostic studies 87
- regional measures, HRQL 117–118
- registries of trials
 Cochrane database 11
 International Clinical Trials Registry 6
- regression 293
- regression analysis 180, 277, 288–293
 linear 290–291
- regulations, clinical research 5–6
- regulatory issues 197
- devices and drugs 203–209
- responsibility 201
- reimbursement, for study centers 265
- relative risk 15, 122
- reliability
 defined 92
 factors influencing 108
 measures of 93–95
 outcome measures 107–108
 types 93
 vs. validity 107
see also agreement
- reliability coefficient 107, 108
- reliability study 91–99
 conducting 95–98
 key steps 98
- reminder form, for patients 263, 264
- reports
 forms for cases 248–257
 preparation 229
- reproducibility
 diagnostic tests 89
 and reliability 91
- research assistants 186, 217
- research design *see* study design
- research ethics board (REB) 204–205
- research evidence, implementation in practice 20–26
- research funding
 grant application tips 212–213
 strategies for obtaining 210–214
- research proposal, example format 150
- research question *see* questions
- research study *see* study
- research team *see* study team
- resources for EBM 11, 22–25
- responsibilities, in research studies 201
- responsiveness to change, HRQL 109–110
- results
 appraisal criteria 66
 discussing with patients 125
 interpreting 98, 139–141
- retrospective cohort study, example 56
- retrospective study
 case–control 50
 defined 56
 example 14
- reviews, systematic *see* systematic reviews
- risk, absolute 123
- S**
- safety, reporting 207
- safety committee 265
- sample size 137, 140, 177–180
 calculation 149, 177, 179
 determining 149
 in reliability study 96–97
- samples
 and populations 269
 statistical 272–274
- sampling distributions 273–274
- scaling, of graphs 289
- screening, of patients 183
- screening form 249–250
- search interface 162
- selection
 of cases and controls 50–51
 patients, in reliability study 96
- selection bias 47, 53, 60, 172
- sensitivity 88, 89
- sensitivity analysis 41, 74, 82–83, 83
- sequential trials, history 4–5
- shadow chart 202
- Short Form-12 113
- Short Form-36 112–113
- Short Musculoskeletal Functional Assessment (SMFA) 118
- Sickness Impact Profile (SIP) 113–114
- significance
 clinical, and confidence intervals 141–142
 clinical vs. statistical 129, 139–142, 287
 statistical 129, 276, 292
 and treatment effect 15
see also P value; statistical analysis/testing
- single-blind studies, history 4
- single-center pilot study, budget 193
- single-event probability 121
- site investigator 217–218
- sites *see* clinical centers/sites; web sites
- skills, individual surgeons 13, 59, 62, 164
- SMFA outcome measure 118
- software
 costs 187, 189
 statistical packages 217
- source documents 248
- Spearman correlation coefficient 306
- Spearman rank correlation 305
- specificity 88, 89
- sponsor 197, 205
- sponsor-investigator 205
- staffing costs 185–186
- standard case 249
- standard deviation (SD) 271, 272, 273
- standard error of the mean (SE) 274, 275
- standard operating procedures (SOPs) 197, 234, 258
- standardized mean difference (SMD) 72
- start-up funding 211
- statistical analysis/testing 277, 279
 calculations 305–308
 choice of tests 283
 conducting 283–287
 guide 269–307
 means and proportions 279–287
see also significance; statistics
- statistical error, types 135–136
- statistical expertise, and EBM 15
- statistical modeling 277
- statistical packages 217
- statistical power *see* power of studies/tests
- statistician, senior 216
- statisticians, costs 185, 186
- statistics
 basic principles 269–278
 descriptive 271–272
 purpose 269
 terminology 15
see also significance; statistical analysis/testing
- steering committee 192, 219, 265
- stratification 168, 262
- stratified randomization 165
- studies
 administration 265
 budgeting for 181–195
 case report forms (CRFs) 248–257
 conducting 215–267
 design *see* study design
 leadership 232
 material 226
 positive vs. negative 72, 129–130
 posters 190

- power *see* power of studies/tests
 sample 269, 272–274
 sponsor 197, 205
 supplies for, costs 190
 team *see* study team
see also clinical research; clinical trials;
 randomized controlled trials; sys-
 tematic reviews; trials
- study design 21
 case-control 49
 classifications 31–36
 comparison of types 171
 experimental vs. observational 32
 expertise-based 62, 166
 hierarchy 21, 37–43
 key concepts 21
 randomized vs. nonrandomized
 44–46
 sample size 177–180
 selecting 146–149
 understanding 47–99
- study team
 description in proposal 150–151
 roles 215–221
 selecting members 150
- subgroup analysis 74
- subjects, selection 96
- supplies for studies, costs 190
- surgery, evidence-based 8–11
- surgical literature, critical appraisal
 98–99
- surgical protocol, standardization
 164–165
- surgical report 252
- systematic reviews 21, 35, 69
 conducting 70–74
 defined 146
 evaluating 74–75
 example 69
 MEDLINE search strategy 163
- T**
- t* test 276
 with Excel 283–285
 multiple, problems with 295
 paired 282–283
 target outcome 238
 target population 269
- team members
 description in proposal 150–151
 selecting 150
- telephone costs 189
- termination of study 235
- terminology, statistics 15
- TESS outcome measure 118
- test-retest reliability 107, 108
- tests
 evaluating 276
 one-tailed vs. two-tailed 282
 power *see* power of studies/tests
 statistical *see* statistical analysis/
 testing
 thresholds 85
 usage 282–283
- therapeutic studies
 hierarchies of study design 39–40
 levels of evidence 38
- thresholds, testing and treatment 85–86
- time horizon, in outcomes 101–102
- timeframe, study plan 150
- Toronto Extremity Salvage Score (TESS)
 118
- travel costs 192–193
- treatment
 levels of evidence for results 38
 threshold 85–86
- treatment effects
 comparing 123
 presentation 121–126
 understanding 121–142
- treatment studies
 hierarchies of study design 39–40
 levels of evidence 38
- trials
 budgeting for 181–195
 committees 219, 229
 interpreting results 124
 investigator- vs. industry-initiated 196
 leadership 232
 need for, protocol description 151
 nonrandomized 170
 organization 168–169, 223
 parallel 33, 63
 positive vs. negative 72, 129–130
see also studies
- troubleshooting, in manual of opera-
 tions 266
- truncation, in searches 160
- two-tailed tests 282
- two-way analysis of variance 298–300
- type I error 132, 136, 149, 166–167,
 276, 280–281
- type II error 136, 149, 276, 280–281
- types of data 282
- U**
- uncertainty
 in diagnostic tests 86–87
 in statistical estimates 127, 128
- univariable analysis 180
- Users' Guide web site 25
- utility measures, HRQL 103, 112,
 114–115, 147
- V**
- validity
 appraisal criteria 66
 diagnostic studies 86
 instruments 92
 outcome measures 107, 108–109
 vs. reliability 107
- variables
 confounding 53, 57, 172, 180
 defined 301
 independent vs. dependent 288
- variance 271, 295–296
see also analysis of variance
- variation, within-group 295
- violation of protocol 199
- W**
- web sites, relevant to EBM 16
- weighted kappa 94–95
- withdrawal from study 57, 167, 199,
 201, 234, 249, 255
 form 255
- within-group variation 295
- WOMAC outcome measure 118
- World Health Organization (WHO) 6